The introduction of small-molecule drugs and humanized monoclonal antibodies as novel therapies that target specific receptors and proteins in specific signal-transduction pathways has renewed interest in genes that had previously been identified as being involved in the tumorigenic process. The first of these genes was the ERBB2 3 [v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)] oncogene (also known as HER2), a member of the epidermal growth factor receptor (EGFR) family, which is amplified in human breast cancer. Diagnostic interests in this gene were never peaked until this receptor became the target of Herceptin, the first monoclonal antibody therapy against a cellular receptor. Similarly, EGFR has become the target of both monoclonal antibody therapies that target the binding domain and small-molecule drugs that inhibit its tyrosine kinase activity. KRAS (v-Kiras2 Kirsten rat sarcoma viral oncogene homolog) is a known oncogene that typically functions in the EGFR pathway. Although mutations in this oncogene are known to be associated with various types of human cancer, only recently has it become an attractive biomarker for the clinical laboratory and healthcare provider as a mechanism to determine therapeutic options. KRAS mutation detection has become part of the standard workup of patients with colorectal cancer, and those tumors that harbor a KRAS mutation have been shown to be nonresponsive to anti-EGFR therapies. The implementation of KRAS mutation testing in a clinical laboratory environment is surveyed below among 4 pathologists and a medical oncologist from 4 leading medical institutions in the US. Currently, specimens are being sent to a reference laboratory for KRAS testing. Requests for KRAS testing come from oncologists who are determining treatment options for patients with colorectal carcinoma. Our laboratory is in the process of validating an assay for KRAS testing for implementation soon.
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: At our institution, the GI Oncology Group is regularly performing KRAS mutation testing on all patients with metastatic colorectal cancer in whom anti-EGFR therapy is being considered. This is in keeping with the American Society of Clinical Oncology Provisional Clinical Opinion published in 2009. Given the lack of response to EGFR inhibitors in patients with KRAS gene mutations, anti-EGFR therapy is not appropriate in this group.
What types of treatment decisions are based on KRAS status, and are retrospective analyses of patients' tumors warranted?
Arief A. Suriawinata: The decision to treat patients with anti-EGFR therapy highly depends upon the KRAS gene mutation status; i.e., anti-EGFR therapy is administered only in patients with wild-type KRAS. Retrospective studies on tumor characteristics may be helpful in predicting the status of KRAS mutation and understanding specific histologic features associated with KRAS mutation; for example, our recent study in colorectal cancer showed that the majority of colorectal cancers with persistent preexisting villous adenoma were KRAS mutation positive.
William K. Funkhouser: Trial data showed that no colorectal carcinoma patient with an activating KRAS mutation has responded to treatment with anti-EGFR antibodies. Carcinomas from patients unresponsive to first-line therapy can be screened retrospectively for the presence of the activating KRAS point mutations in codons 12, 13, and 61 by use of DNA template extracted from paraffin blocks.
Marc Ladanyi: KRAS mutations are a very strong negative predictor of response to EGFR-targeted therapies in both lung adenocarcinoma and colorectal carcinoma. If no current sample is available for testing, retrospective analysis of a patient's initial surgical sample is useful, as KRAS mutations are typically present at diagnosis and are maintained throughout the course of the disease. Of course, the possibility of second or multiple primary cancers must be kept in mind. Jan A. Nowak: Multiple studies have shown that patients with metastatic colorectal tumors that harbor KRAS codon 12 and 13 mutations do not benefit from treatment with cetuximab or panitumumab. Patients whose tumors have wild-type codon 12 and 13 sequences show a partial response to those agents. For patients who had been started on such therapy, KRAS testing would be useful in determining the potential of continued use of those agents. 
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Detection of somatic mutations in potentially heterogeneous tumors can be problematic. How does this affect your interpretation of these test results?
Arief A. Suriawinata: While we make the best effort to select a section that is most representative of the tumor for KRAS testing, we realize that, although rare, tumor heterogeneity can be a problem in large colorectal cancers with a few different lines of differentiation. Alternatively, KRAS testing can be performed in a metastasis that presumably represents the most aggressive clone if tumor heterogeneity is suspected. Our laboratory uses 5% controls for each of the 7 mutations that consist of wildtype and mutant synthetic oligonucleotides mixed at a 95:5 ratio, respectively. My concern with laboratories reporting the detection of multiple KRAS mutations in the same tumor is that this may reflect some technical challenges in assay performance due to the close proximity of the bases that are typically mutated (codons 12 and 13) vs true tumor heterogeneity.
William K. Funkhouser: Routine admixture of wildtype and mutant KRAS DNA implies a need for a high sensitivity for detection of the point mutations in codons 12, 13, and 61. We use spiked 5% positive controls and use pyrosequencing for detection of the point mutations. Sanger sequencing would be less sensitive, and melt-curve analysis would require confirmatory sequencing.
Marc Ladanyi: In our experience, key early driver genetic alterations such as KRAS mutations (or EGFR mutations) rarely if ever show genuine intratumoral heterogeneity. It is likely that most situations with apparent intratumoral heterogeneity for KRAS mutations actually represent testing of areas of differing tumor content, some of which may be below the sensitivity level of the testing method (typically Sanger sequencing). Other instances of heterogeneity for KRAS mutations may represent separate primaries. We have seen several patients with multiple primary lung adenocarcinomas, each containing a different mutation (EGFR or KRAS). Jan A. Nowak: I am not aware that anyone has systematically addressed the issue of potential tumor heterogeneity with regard to KRAS mutation in colorectal tumors. Until there are good data, this will remain a hypothetical problem. We do know, however, that some 30%-40% of colon tumors will have KRAS mutations and that these tumors are not likely to respond to the anti-EGFR agents noted above. Assays that are similar in design and methodology should be as predictive as those used to establish the KRAS-EGFR observation. These are the assays laboratories are currently performing. Should tumor microheterogeneity be shown to be a factor, then the interpretation of KRAS test results will have to take that into account. Whether tumors that show significant KRAS heterogeneity will respond differently to anti-EGFR therapies is also unknown.
J. Marc Pipas:
At our institution, we have experience with in-house testing for somatic KRAS mutations through use of real-time PCR and TaqMan probe chemistries. We have shown that this is a reliable, user-friendly, and robust method that can be used for low-volume testing using paraffin-embedded tissue specimens as well as material from fine-needle aspiration samples preserved in alcoholbased fixatives. We believe that this approach is reasonable for widespread clinical testing.
Do you think KRAS mutation testing will be extended to other tumor types?
Arief A. Suriawinata: Testing of other tumor types would only occur if the therapeutics can target this signal-transduction pathway in these other tumor types. Because EGFR also plays a significant role in other tumors, this scenario is highly likely.
William K. Funkhouser: KRAS mutation screening should be considered for any malignancy in which treatment of upstream kinases with antibodies or tyrosine kinase inhibitors is being considered. BRAF mutation screening should also be considered, since acti-vating BRAF mutations could also preclude response to anti-EGFR therapy.
Marc Ladanyi: Currently, KRAS mutations are used as negative predictors of response to EGFR-targeted therapies, so the tumor types tested are those where EGFR-targeted therapies are already in widespread use, i.e., lung adenocarcinoma and colorectal carcinoma. However, targeted approaches to KRAS mutant cancers themselves are in various stages of clinical developmentand are likely to drive the expansion of KRAS testing across a wider range of tumor histologies. Jan A. Nowak: It is likely. KRAS mutations are downstream activators of the EGFR signaling pathway, presumably the mechanism by which those mutations circumvent the efficacy of EGFR antagonists. In nonsmall cell lung cancer, KRAS mutations and EGFR mutations are reportedly mutually exclusive. It is likely that KRAS mutation testing will be part of the algorithm for evaluation of the EGFR pathway in nonsmall cell lung cancer.
J. Marc Pipas: KRAS testing, as well as testing of other components of the EGFR-MAPK signal-transduction pathway (such as BRAF), will continue to be evaluated in other tumor types and clinical scenarios. In addition, as other components of tumor metabolic pathways are discovered, these will certainly be pursued as possible prognostic and predictive factors in a variety of other cancers. 
